1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > EpiCast Report: Fibromyalgia - Epidemiology Forecast to 2023

EpiCast Report: Fibromyalgia - Epidemiology Forecast to 2023

Summary

Fibromyalgia, also known as fibromyalgia syndrome and fibrositis, is a common form of nonarticular rheumatism that is associated with chronic, widespread musculoskeletal pain, generalized tender joints, fatigue, and a long list of wide-ranging symptoms, such as fatigue, sleep disturbances, irritable bowel syndrome (IBS), headaches, and depression. Fibromyalgia is a complex illness to diagnose and treat, as it is idiopathic, and its symptoms may be part of or overlap with other diseases.

For this analysis, GlobalData epidemiologists defined fibromyalgia using the International Classification of Diseases, Ninth Revision (ICD-9) code for fibromyalgia (729.1) and the International Classification of Diseases, Tenth Revision (ICD-10) code for fibromyalgia (M79.7). GlobalData epidemiologists used country-specific studies that provided the total prevalence of fibromyalgia using the 2010 American College of Rheumatology (ACR) classification criteria for this epidemiological forecast.

In 2013, there were 23,663,533 total prevalent cases of fibromyalgia in the 7MM. GlobalData epidemiologists forecast that the total prevalent cases in the 7MM will increase to 24,881,838 by 2023, at an Annual Growth Rate (AGR) of 0.51%. All markets, except for Germany and Japan, will see a small increase in the number of cases at varying AGRs. Since GlobalData epidemiologists held the prevalence constant throughout the forecast period, the differences observed in the total prevalent cases of fibromyalgia in the 7MM are driven by changes in the underlying population dynamics of each market.

In the 7MM, fibromyalgia epidemiological studies have shown that women have a higher total prevalence of fibromyalgia compared with men. When the 1990 ACR criteria were used to define fibromyalgia, a majority of patients with fibromyalgia were women due to the greater number of female body tender points. However, the 2010 ACR criteria are entirely symptom-based, do not require tender point counts, and provide a more accurate sex distribution of total prevalent cases of fibromyalgia (Wolfe et al., 2011). Additional studies are needed to clarify the etiology of the association between sex and fibromyalgia.

Scope

- The Fibromyalgia EpiCast Report provides an overview of the risk factors, global, and historical trends of fibromyalgia in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiology forecast of fibromyalgia total prevalent cases segmented by age (in five-year increments for all ages), sex, and pain severity (mild, moderate, and severe) in these seven markets.
- The fibromyalgia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buye

- Develop business strategies by understanding the trends shaping and driving the global fibromyalgia market.
- Quantify patient populations in the global fibromyalgia market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for fibromyalgia therapeutics in each of the markets covered.
- Identify the percentage of fibromyalgia total prevalent cases by severity.

Table Of Contents

EpiCast Report: Fibromyalgia - Epidemiology Forecast to 2023
1 Table of Contents
1 Table of Contents 3

2 Introduction 6
2.1 Catalyst 6
2.2 Related Reports 7
2.3 Upcoming Related Reports 7
3 Epidemiology 8
3.1 Disease Background 8
3.2 Risk Factors and Comorbidities 8
3.3 Global Trends 10
3.3.1 US 12
3.3.2 5EU 12
3.3.3 Japan 12
3.4 Forecast Methodology 13
3.4.1 Sources Used 13
3.4.2 Sources Not Used 17
3.4.3 Forecast Assumptions and Methods - Total Prevalent Cases of Fibromyalgia 18
3.4.4 Forecast Assumptions and Methods - Fibromyalgia Pain Severity 20
3.5 Epidemiological Forecast for Fibromyalgia (2013-2023) 21
3.5.1 Total Prevalent Cases of Fibromyalgia 21
3.5.2 Age-Specific Total Prevalent Cases of Fibromyalgia 23
3.5.3 Sex-Specific Total Prevalent Cases of Fibromyalgia 25
3.5.4 Age-Standardized Total Prevalence of Fibromyalgia 27
3.5.5 Total Prevalent Cases of Fibromyalgia by Pain Severity 28
3.6 Discussion 30
3.6.1 Epidemiological Forecast Insight 30
3.6.2 Limitations of the Analysis 32
3.6.3 Strengths of the Analysis 33
4 Appendix 34
4.1 Bibliography 34
4.2 About the Authors 37
4.2.1 Epidemiologists 37
4.2.2 Reviewers 37
4.2.3 Global Director of Therapy Analysis and Epidemiology 38
4.2.4 Global Head of Healthcare 39
4.3 About GlobalData 40
4.4 About EpiCast 40
4.5 Disclaimer 41

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Fibromyalgia 9
Table 2: Comparison of the ACR Criteria for Fibromyalgia Classification 11
Table 3: 7MM, Sources of Total Prevalence Data Used to Forecast the Total Prevalent Cases of Fibromyalgia 13
Table 4: 7MM, Sources of Fibromyalgia Pain Severity Data Used to Forecast the Total Prevalent Cases of Fibromyalgia Segmented by Pain Severity 14
Table 5: 7MM, Total Prevalent Cases of Fibromyalgia, Ages ?10 Years, Both Sexes, N, Selected Years 2013-2023 22
Table 6: 7MM, Age-Specific Total Prevalent Cases of Fibromyalgia, Both Sexes, N (Row %), 2013 24
Table 7: 7MM, Sex-Specific Total Prevalent Cases of Fibromyalgia, Ages ?10 Years, N (Row %), 2013 26
Table 8: 7MM Total Prevalent Cases of Fibromyalgia, N (%), by Pain Severity, Both Sexes, Ages ?10 Years, 2013 29

1.2 List of Figures
Figure 1: 7MM, Total Prevalent Cases of Fibromyalgia Ages ?10 Years, Both Sexes, N, 2013-2023 23
Figure 2: 7MM, Age-Specific Total Prevalent Cases of Fibromyalgia, Both Sexes, N, 2013 25
Figure 3: 7MM, Sex-Specific Total Prevalent Cases of Fibromyalgia, Ages ?10 Years, N, 2013 27
Figure 4: 7MM, Age-Standardized Total Prevalence of Fibromyalgia (%), Ages ?10 Years, by Sex, 2013 28
Figure 5: 7MM Total Prevalent Cases of Fibromyalgia (N), by Pain Severity, Both Sexes, Ages ?10 Years, 2013 30

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Neuropathic  Pain - Market Insights, Epidemiology and Market Forecast-2023

Neuropathic  Pain - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Neuropathic Pain - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Fibromyalgia  - Market Insights, Epidemiology and Market Forecast-2023

Fibromyalgia  - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • March 2017
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Fibromyalgia - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...

Global Market Study on Neuropathic Pain: Anticonvulsants Drug Class Segment Projected to Witness the Highest Growth Through 2024

Global Market Study on Neuropathic Pain: Anticonvulsants Drug Class Segment Projected to Witness the Highest Growth Through 2024

  • $ 4900
  • Industry report
  • November 2016
  • by Persistence Market Research

This Persistence Market Research report examines the global neuropathic pain market for the period 2016–2024. The primary objective of the report is to offer updates and information related to market ...


ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.